Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | ADH7 | P40394 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.36 |
| ▸ | GAPDH | P04406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8079439 | 0.98 | ACE2 (0.48) | ACE2OPRM1GPR84SPHK1FFAR1 | |
| SCHEMBL14336195 | 0.98 | ACE2 (0.48) | ACE2OPRM1GPR84SPHK1FFAR1 | |
| SCHEMBL10938434 | 0.98 | ACE2 (0.48) | ACE2OPRM1GPR84SPHK1FFAR1 | |
| SCHEMBL448296 | 0.98 | ACE2 (0.48) | ACE2OPRM1GPR84SPHK1FFAR1 | |
| SCHEMBL1410326 | 0.93 | — | — | |
| SCHEMBL7298035 | 0.84 | FFAR1 (0.40) | FFAR1FFAR4 | |
| SCHEMBL7298037 | 0.84 | FFAR1 (0.40) | FFAR1FFAR4 | |
| SCHEMBL269374 | 0.82 | — | — | |
| SCHEMBL9258970 | 0.82 | ACE2 (0.34) | ACE2OPRM1FDPS | |
| SCHEMBL7289277 | 0.81 | FAAH (0.36) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170065575-A1 | NAMPT INHIBITORS | ABBVIE INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20150141398-A1 | NAMPT INHIBITORS | ABBVIE INC. | 2015-05-21 | — | — | US | disclosed |
| EP-2295470-B1 | CELLULOSE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF, CELLULOSE RESIN COMPOSITION, MOLDED ARTICLE AND METHOD FOR PRODUCTION THEREOF, AND HOUSING FOR ELECTROCHEMICAL DEVICE | FUJIFILM CORP (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-20110098463-A1 | CELLULOSE DERIVATIVE AND METHOD FOR PRODUCING THE SAME, CELLULOSE RESIN COMPOSITION, MOLDED MATTER AND METHOD FOR MAKING THE SAME, AND ELECTRICAL AND ELECTRONIC EQUIPMENT HOUSING | FUJIFILM CORPORATION (JP) | 2011-04-28 | — | — | US | disclosed |
| EP-2295470-A1 | CELLULOSE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF, CELLULOSE RESIN COMPOSITION, MOLDED ARTICLE AND METHOD FOR PRODUCTION THEREOF, AND HOUSING FOR ELECTROCHEMICAL DEVICE | FUJIFILM Corporation (JP) | 2011-03-16 | — | — | EP | disclosed |
| CN-1798739-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2006-07-05 | — | — | CN | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0583971-A1 | Piperidine derivatives | SANKYO COMPANY LIMITED (JP) | 1994-02-23 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141398-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | ACE2 2079/4885OPRM1 1658/4885GPR84 2987/4885 |
| US-20170065575-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | ACE2 2079/4885OPRM1 1658/4885GPR84 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.